CLRB

Cellectar Biosciences Inc

CLRB.US cellectar.com + Research + Basket
CIK 0001279704
Employees 11
Phone 608 441 8120
Fiscal year end December
IPO Nov 10, 2005
Address 100 Campus Drive, Florham Park, NJ, United States, 07932
1.21
-0.02 (-1.23%)
USD · NASDAQ
52-week range
1.12
4.70
Trading at 2% of the 52-week range
Market Cap
11.53M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.62
Div. Yield
N/A
% Institutions
34.71%
% Insiders
1.75%

1 Year

-63.0%

3 Year

-98.3%

10 Year

-100.0%
Description

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Actions

Add an action for CLRB.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. James V. Caruso President, CEO & Director 1959
Mr. Chad J. Kolean CPA VP, CFO & Secretary 1964
Mr. Jarrod Longcor Chief Operating Officer 1973

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Dec 12, 2025 John Neis N/A Sale 198.00 $3.70 $732.60 SEC
Jul 02, 2025 Chad J Kolean N/A Purchase 5.00K $4.99 $24.95K SEC
Jul 02, 2025 James V Caruso N/A Purchase 10.00K $4.99 $49.90K SEC
Jul 02, 2025 Jarrod Longcor N/A Purchase 10.00K $4.99 $49.90K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Caligan Partners LP 470.00K Jun 30, 2026 4.97% $0.06 0.00%
Nantahala Capital Management, LLC 440.00K Jun 30, 2026 4.66% $0.02 0.00%
StemPoint Capital LP 354.94K Jun 30, 2026 3.76% $0.17 0.00%
Vanguard Capital Management, LLC 327.37K Jun 30, 2026 3.46% $0.00 299.79%
SILVERARC CAPITAL MANAGEMENT, LLC 321.73K Jun 30, 2026 3.40% $0.09 0.00%
Bleichroeder LP 288.68K Jun 30, 2026 3.05% $0.14 188.68%
Jupiter Topco LLC 274.16K Jun 30, 2026 2.90% $0.00 0.00%
Balyasny Asset Management LLC 220.00K Jun 30, 2026 2.33% $0.00 0.00%
Empery Asset Management, LP 189.61K Jun 30, 2026 2.01% $0.61 0.00%
Diadema Partners LP 138.34K Jun 30, 2026 1.46% $0.05 0.00%
Stonepine Capital Management Llc 104.55K Jun 30, 2026 1.11% $0.16 0.00%
Persistent Asset Partners Limited 92.98K Jun 30, 2026 0.98% $0.08 0.00%
BOOTHBAY FUND MANAGEMENT, LLC 85.07K Jun 30, 2026 0.90% $0.00 0.00%
Geode Capital Management, LLC 53.35K Jun 30, 2026 0.56% $0.00 1.09%
Vanguard Fiduciary Trust Co 46.22K Jun 30, 2026 0.49% $0.00 178.89%
Sequoia Financial Advisors LLC 21.85K Jun 30, 2026 0.23% $0.00 15.92%
Acadian Asset Management LLC 16.58K Jun 30, 2026 0.18% $0.00 0.00%
Northern Trust Corp 14.84K Jun 30, 2026 0.16% $0.00 0.00%
Riverview Capital Advisers LLC 10.38K Jun 30, 2026 0.11% $0.01 0.00%
BlackRock Inc 4.74K Jun 30, 2026 0.05% $0.00 -0.21%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 184.15K 1.95% ▲ 0.00% Sep 30, 2026
2 Fidelity Extended Market Index 47.05K 0.50% ▲ 10.66% Aug 31, 2026
3 Abante Quant Value FI 36.31K 0.38% ▲ 0.00% Aug 31, 2026
4 Fidelity Series Total Market Index 10.50K 0.11% ▲ 86.05% Aug 31, 2026
5 Fidelity Total Market Index 3.59K 0.04% ▲ 73.74% Aug 31, 2026

Financial Highlights

▼
Market Cap: $11.53M
EBITDA: $-23.36M
PEG Ratio: $0.00
Book Value: $3.62
Earnings/Share: $-3.46
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -58.44%
ROE (TTM): -119.57%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-20.69M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 9.45M
Shares Float: 9.28M
% Insiders: 1.75%
% Institutions: 34.71%
Shares Short: 263.52K
Shares Short (Prior Month): 166.27K
Short Ratio: 1.95
Short % Float: 2.80%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-213.60K
Gross Profit
subtotal
$-213.60K
SG&A
adjust
$-11.48M
R&D
adjust
$-11.50M
Operating Income
subtotal
$-22.98M
Other / Non-Operating Items
adjust
$1.19M
Net Income
subtotal
$-21.79M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CLRB.US!